Personalized medicine - Where do we stand? Pouring some water into wine: A realistic perspective

Croatian Medical Journal

Volumn 53, Issue 4, 2012, Pages 314-320

  Gundert Remy, Ursula ^a   Dimovski, Aleksandar ^b   Gajović, Srećko ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b SS Cyril and Methodius University Faculty of Pharmacy   (Macedonia)

^c UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; CLOPIDOGREL; CRIZOTINIB; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; DEBRISOQUINE; DOCETAXEL; DOUBLE STRANDED DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MEPHENYTOIN; MICRORNA; PERTUZUMAB; TRASTUZUMAB; WARFARIN;

ACETYLATION; ANTICOAGULANT THERAPY; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CANCER THERAPY; CLINICAL DECISION MAKING; CLINICAL PRACTICE; COLORECTAL CANCER; DISEASE FREE SURVIVAL; DNA SEQUENCE; DRUG HALF LIFE; DRUG RESPONSE; EMPLOYMENT; ENVIRONMENTAL FACTOR; GENE AMPLIFICATION; GENE DUPLICATION; GENE FREQUENCY; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENOTYPE; HEALTH INSURANCE; HLA SYSTEM; HUMAN; HYDROXYLATION; LUNG CARCINOMA; METABOLIC CAPACITY; MOLECULAR DIAGNOSIS; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PHENOTYPE; PLASMA CONCENTRATION-TIME CURVE; PROGRESSION FREE SURVIVAL; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; TREATMENT OUTCOME;

BIOLOGICAL MARKERS; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; COLORECTAL NEOPLASMS; DRUG APPROVAL; GENETIC TESTING; GENOMICS; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR TARGETED THERAPY; PHARMACOGENETICS; PHARMACOKINETICS;

EID: 84866452075     PISSN: 03539504     EISSN: 13328166     Source Type: Journal    
DOI: 10.3325/cmj.2012.53.314     Document Type: Article

References (37)

1. Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med. 2010;363:301-4.
2. Louca S. Personalized medicine - a tailored health care system - challenges and opportunities. Croat Med J. 2012;53:211-3.
3. Evans WE, McLeod HL. Pharmacogenomics - drug disposition, drug targets, and side effects. N Engl J Med. 2003;348:538-49.
4. Weinshilboum R. Inheritance and drug response. N Engl J Med. 2003;348:529-37.
5. Angelo M, Ding LG, Lancaster R, Latham A, Smith RL. A correlation between the response to debrisoquine and the amount of unchanged drug excreted in the urine. Br J Pharmacol. 1975;55:264P.
6. Eichelbaum M, Spannbrucker N, Dengler HJ. Proceedings: N-oxidation of sparteine in man and its interindividual differences. Naunyn Schmiedebergs Arch Pharmacol. 1975;287 Suppl:R94.
7. Balant L, Gorgia A, Tschopp JM, Revillard C, Fabre J. Pharmacokinetics of two beta blocking drugs: detection of a pharmacogenetic abnormality. Schweiz Med Wochenschr. 1976;106:1403-7.
8. Gonzalez FJ, Skoda RC, Kimura S, Umeno M, Zanger UM, Newbert DW, et al. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature. 1988;331:442-6.
9. Kimura S, Umeno M, Skoda RC, Meyer UA, Gonzales F. The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am J Hum Genet. 1989;45:889-904.
10. Balant LP, Gundert-Remy U, Boobis A, von Bahr C. Relevance of genetic polymorphism in drug metabolism in the development of new drugs. Eur J Clin Pharmacol. 1989;36:551-4.
11. Alvan G, Bechtel P, Iselius L, Gundert-Remy U. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol. 1990;39:533-7.
12. Meyer UA. Pharmacogenetics - five decades of therapeutic lessons from genetic diversity. Nat Rev Genet. 2004;5:669-76.
13. Shams ME, Arneth B, Hiemke C, Dragicevic A, Müller MJ, Kaiser R, et al. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther. 2006;31:493-502.
14. Sistonen J, Madadi P, Ross CJ, Yazdanpanah M, Lee JW, Landsmeer ML, et al. Prediction of codeine toxicity in infants and their mothers using a novel combination of maternal genetic markers. Clin Pharmacol Ther. 2012;91:692-9.
15. Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, Soranzo N, et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 2009;5:e1000433.
16. Kangelaris KN, Bent S, Nussbaum RL, Garcia DA, Tice JA. Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin. J Gen Intern Med. 2009;24:656-64.
17. Caraco Y, Blotnick S, Muszkat M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther. 2008;83:460-70.
18. Johnson JA, Roden DM, Lesko LJ, Ashley E, Klein TE, Shuldiner AR. Clopidogrel: a case for indication-specific pharmacogenetics. Clin Pharmacol Ther. 2012;91:774-6.
19. Harmsze AM, van Werkum JW, Hackeng CM, Ruven HJ, Kelder JC, Bouman HJ, et al. The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting. Pharmacogenet Genomics. 2012;22:169-75.
20. Becquemont L, Alfirevic A, Amstutz U, Brauch H, Jacqz-Aigrain E, Laurent-Puig P, et al. Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics. Pharmacogenomics. 2011;12:113-24.
21. Daly AK, Day CP. Genetic association studies in drug-induced liver injury. Drug Metab Rev. 2012;44:116-26.
22. Daly AK. Using genome-wide association studies to identify genes important in serious adverse drug reactions. Annu Rev Pharmacol Toxicol. 2012;52:21-35.
23. International Consortium for Blood Pressure Genome-Wide Association Studies, Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature. 2011;478:103-9.
24. Kitsios GD, Kent DM. Personalised medicine: not just in our genes. BMJ. 2012;344:e2161.
25. O'Donnell CJ, Nabel EG. Genomics of cardiovascular disease. N Engl J Med. 2011;365:2098-109.
26. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science. 1987;235:177
27. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673-84.
28. Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, et al; CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366:109-19.
29. DeRoock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11:753-62.
30. Yi ES, Chung JH, Kulig K, Kerr KM. Detection of anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer and related issues in alk inhibitor therapy: a literature review. Mol Diagn Ther. 2012;16:143-50.
31. Longo DL. Tumor heterogeneity and personalized medicine. N Engl J Med. 2012;366:956-7.
32. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883-92.
33. Zhao Q, Zhang Y. Epigenome sequencing comes of age in development, differentiation and disease mechanism research. Epigenomics. 2011;3:207-20.
34. Ritchie MD. Using biological knowledge to uncover the mystery in the search for epistasis in genome-wide association studies. Ann Hum Genet. 2011;75:172-82.
35. Freedman AN, Sansbury LB, Figg WD, Potosky AL, Weiss Smith SR, Khoury MJ, et al. Cancer pharmacogenomics and pharmacoepidemiology: settinga research agenda to accelerate translation. J Natl Cancer Inst. 2010;102:1698-705.
36. Stanek EJ, Sanders CL, Taber KA, Khalid M, Patel A, Verbrugge RR, et al. Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey. Clin Pharmacol Ther. 2012;91:450-8.
37. Lorgis V, Algros MP, Villanueva C, Chaigneau L, Thierry-Vuillemin A, Nguyen T, et al. Discordance in early breast cancer for tumour grade, estrogen receptor, progesterone receptors and human epidermal receptor-2 status between core needle biopsy and surgical excisional primary tumor. Breast. 2011;20:284-7.